480 related articles for article (PubMed ID: 33212364)
21. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
[TBL] [Abstract][Full Text] [Related]
22. Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient-Derived Xenografts.
Mohamed Suhaimi NA; Phyo WM; Yap HY; Choy SHY; Wei X; Choudhury Y; Tan WJ; Tan LAPY; Foo RSY; Tan SHS; Tiang Z; Wong CF; Koh PK; Tan MH
Mol Cancer Ther; 2017 Sep; 16(9):2035-2044. PubMed ID: 28533437
[TBL] [Abstract][Full Text] [Related]
23. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
Zhang H; Yuan L; Liu L; Yan C; Cheng J; Fu Q; Tong Z; Jiang W; Zheng Y; Zhao P; Zhang G; Fang W
BMC Cancer; 2020 May; 20(1):416. PubMed ID: 32404198
[TBL] [Abstract][Full Text] [Related]
24. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
[TBL] [Abstract][Full Text] [Related]
25. Modeling rectal cancer to advance neoadjuvant precision therapy.
Janakiraman H; Zhu Y; Becker SA; Wang C; Cross A; Curl E; Lewin D; Hoffman BJ; Warren GW; Hill EG; Timmers C; Findlay VJ; Camp ER
Int J Cancer; 2020 Sep; 147(5):1405-1418. PubMed ID: 31989583
[TBL] [Abstract][Full Text] [Related]
26. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.
Katsila T; Juliachs M; Gregori J; Macarulla T; Villarreal L; Bardelli A; Torrance C; Elez E; Tabernero J; Villanueva J
Clin Cancer Res; 2014 Dec; 20(24):6346-56. PubMed ID: 25324142
[TBL] [Abstract][Full Text] [Related]
27. HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer.
Ciardiello F; Normanno N
Cancer Discov; 2011 Nov; 1(6):472-4. PubMed ID: 22586650
[TBL] [Abstract][Full Text] [Related]
28. Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity Testing.
Behrens D; Pfohl U; Conrad T; Becker M; Brzezicha B; Büttner B; Wagner S; Hallas C; Lawlor R; Khazak V; Linnebacher M; Wartmann T; Fichtner I; Hoffmann J; Dahlmann M; Walther W
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136299
[TBL] [Abstract][Full Text] [Related]
29. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
[TBL] [Abstract][Full Text] [Related]
30. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
31. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
32. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
Fabian P; Berkovcová J
Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
[TBL] [Abstract][Full Text] [Related]
33. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
35. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
36. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
37. Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
Woolston A; Khan K; Spain G; Barber LJ; Griffiths B; Gonzalez-Exposito R; Hornsteiner L; Punta M; Patil Y; Newey A; Mansukhani S; Davies MN; Furness A; Sclafani F; Peckitt C; Jiménez M; Kouvelakis K; Ranftl R; Begum R; Rana I; Thomas J; Bryant A; Quezada S; Wotherspoon A; Khan N; Fotiadis N; Marafioti T; Powles T; Lise S; Calvo F; Guettler S; von Loga K; Rao S; Watkins D; Starling N; Chau I; Sadanandam A; Cunningham D; Gerlinger M
Cancer Cell; 2019 Jul; 36(1):35-50.e9. PubMed ID: 31287991
[TBL] [Abstract][Full Text] [Related]
38. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
[TBL] [Abstract][Full Text] [Related]
39. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.
Greening DW; Lee ST; Ji H; Simpson RJ; Rigopoulos A; Murone C; Fang C; Gong S; O'Keefe G; Scott AM
Oncotarget; 2015 Nov; 6(35):38166-80. PubMed ID: 26517691
[TBL] [Abstract][Full Text] [Related]
40. Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models.
Prasetyanti PR; van Hooff SR; van Herwaarden T; de Vries N; Kalloe K; Rodermond H; van Leersum R; de Jong JH; Franitza M; Nürnberg P; Todaro M; Stassi G; Medema JP
Int J Cancer; 2019 Jan; 144(2):366-371. PubMed ID: 30151914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
